Prohaska W, Kretschmer V
Infusionsther Klin Ernahr. 1984 Dec;11(6):342-4. doi: 10.1159/000221691.
Cryoprecipitates (CP) and cryodepleted plasma (CDP) were prepared from fresh frozen plasma (FFP). Plasma was easily and cleanly frozen at -50 degrees C using a methanol-bath Ultracryostat, which has been available commercially for the past few years. From a random sample (n = 6), factors VIII:C, IX:C, V:C, fibrinogen, antithrombin III and fibronectin were determined. Concerning the total contents and the in-vitro-recovery of factor VIII:C (x:104 IU/53.5%) and fibrinogen x:175 mg/36.9%), the preparation method was as efficient as other equally common methods. Apart from the well-known applications, CP may be used for the substitution of fibronectin (x:46.2 mg/73.0%). The supernatant plasma of cryoprecipitation (CDP) can be utilized for substitution of coagulation disorders especially deficiencies of the prothrombincomplex and antithrombin III (x:IX:C:183 IU/76.2%; V:C:140.5 U/73.8%; AT III:162 U/80.2%).
冷沉淀(CP)和冷沉淀血浆(CDP)由新鲜冰冻血浆(FFP)制备而成。使用甲醇浴超低温恒温器,血浆在-50℃下能轻松且干净地冻结,这种仪器在过去几年已有商业供应。从一个随机样本(n = 6)中,测定了凝血因子VIII:C、IX:C、V:C、纤维蛋白原、抗凝血酶III和纤连蛋白。关于凝血因子VIII:C的总含量和体外回收率(x:104 IU/53.5%)以及纤维蛋白原(x:175 mg/36.9%),该制备方法与其他同样常见的方法一样有效。除了众所周知的应用外,冷沉淀可用于替代纤连蛋白(x:46.2 mg/73.0%)。冷沉淀的上清血浆(CDP)可用于替代凝血障碍,尤其是凝血酶原复合物和抗凝血酶III缺乏症(x:IX:C:183 IU/76.2%;V:C:140.5 U/73.8%;AT III:162 U/80.2%)。